Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: Cold-adapted vaccine versus DNA prime-adenovirus boost strategies

Vaccine

Volumn 26, Issue 17, 2008, Pages 2062-2072

  Lo, Chia Yun ^a   Wu, Zhengqi ^a   Misplon, Julia A ^a   Price, Graeme E ^a   Pappas, Claudia ^b   Kong, Wing Pui ^c   Tumpey, Terrence M ^b   Epstein, Suzanne L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Heterosubtypic immunity; Influenza; Pandemic

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; INFLUENZA VACCINE; NUCLEOPROTEIN; PROTEIN; SERYLLEUCYLLEUCYLTHREONYLGLUTAMYLVALYLGLUTAMYLTHREONYLPROLYLISOLEUCYL ARGINYLASPARAGINYLGLUTAMYLTRYPTOPHYLGLYCYLCYSTEINYLARGINYLCYSTEINYLASPAR AGINYLGLYCYLSERYLSERYLASPARTIC ACID; THREONYLTYROSYLGLUTAMINYLARGINYLTHREONYLARGINYLALANYLLEUCYLVALINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HETEROSUBTYPIC IMMUNITY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CROSS REACTIONS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 41649119921     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.047     Document Type: Article

References (43)

1. Schulman J.L., and Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 89 (1965) 170-174
2. Yetter R.A., Lehrer S., Ramphal R., and Small Jr. P.A. Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 29 (1980) 654-662
3. Liang S., Mozdzanowska K., Palladino G., and Gerhard W. Heterosubtypic immunity to influenza type A virus in mice: effector mechanisms and their longevity. J Immunol 152 (1994) 1653-1661
4. Epstein S.L. Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti-Infect Ther 1 4 (2003) 627-638
5. Webster R.G., and Askonas B.A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 10 (1980) 396-401
6. Murphy B.R., and Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Vir Immunol 15 2 (2002) 295-323
7. Armerding D., Rossiter H., Ghazzouli I., and Liehl E. Evaluation of live and inactivated influenza-A virus-vaccines in a mouse model. J Infect Dis 145 3 (1982) 320-330
8. Tannock G.A., Paul J.A., and Barry R.D. Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 43 2 (1984) 457-462
9. Tannock G.A., and Paul J.A. Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca. Arch Virol 92 1/2 (1987) 121-133
10. Mak N.K., Zhang Y.H., Ada G.L., and Tannock G.A. Humoral and cellular-responses of mice to infection with a cold-adapted influenza A virus variant. Infect Immun 38 1 (1982) 218-225
11. Wareing M.D., Watson J.M., Brooks M.J., and Tannock G.A. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza A vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. J Med Virol 65 1 (2001) 171-177
12. Wareing M.D., and Tannock G.A. Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57. Vaccine 21 23 (2003) 3097-3100
13. + cytokine responses in mice reveal differences in the relative immunogenicity of cold-adapted influenza-A vaccine donor strains. Vaccine 23 31 (2005) 4075-4081
14. Powell T.J., Strutt T., Reome J., Hollenbaugh J.A., Roberts A.D., Woodland D.L., et al. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 178 2 (2007) 1030-1038
15. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
16. + T cells can promote survival and recovery after challenge. Int Immunol 12 1 (2000) 91-101
17. Epstein S.L., Tumpey T.M., Misplon J.A., Lo C.-Y., Cooper L.A., Subbarao K., et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8 8 (2002) 796-801
18. Epstein S.L., Kong W.P., Misplon J.A., Lo C.-Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 46/47 (2005) 5404-5410
19. Tompkins S.M., Zhao Z.S., Lo C.-Y., Misplon J.A., Liu T., Ye Z.P., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13 3 (2007) 426-435
20. Chen K.-S., and Quinnan Jr. G.V. Induction, persistence and strain specificity of haemagglutinin-specific secretory antibodies in lungs of mice after intragastric administration of inactivated influenza virus vaccines. J Gen Virol 69 (1988) 2779-2784
21. Smeenk C.A., and Brown E.G. The influenza-virus variant A/FM/1/47-MA possesses single amino-acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. J Virol 68 1 (1994) 530-534
22. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79 18 (2005) 11788-11800
23. Barouch D.H., Yang Z.Y., Kong W.P., Korioth-Schmitz B., Sumida S.M., Truitt D.M., et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79 14 (2005) 8828-8834
24. Benton K.A., Misplon J.A., Lo C.-Y., Brutkiewicz R.R., Prasad S.A., and Epstein S.L. Heterosubtypic immunity to influenza A virus in mice lacking either IgA, all Ig, NKT cells, or γδ T cells. J Immunol 166 (2001) 7437-7445
25. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 10 (1999) 1157-1163
26. Claas E.C.J., Osterhaus A.D.M.E., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 (1998) 472-477 Feb. 14
27. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355 24 (2006) 2513-2522
28. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 2 (2000) 168-175
29. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., et al. Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 3 5 (2007) 157-164
30. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., and Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13 15 (1995) 1399-1402
31. Frace A.M., Klimov A.I., Rowe T., Black R.A., and Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17 18 (1999) 2237-2244
32. Mozdzanowska K., Feng J.Q., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21 19/20 (2003) 2616-2626
33. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. Plos Medicine 3 9 (2006) 1541-1555
34. Lu X.H., Edwards L.E., Desheva J.A., Nguyen D.C., Rekstin A., Stephenson I., et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24 44-46 (2006) 6588-6593
35. Desheva J.A., Lu X.H., Rekstin A.R., Rudenko L.G., Swayne D.E., Cox N.J., et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24 47/48 (2006) 6859-6866
36. Suzuki Y., and Nei M. Origin and evolution of influenza virus hemagglutinin genes. Mol Biol Evol 19 4 (2002) 501-509
37. Evans R.K., Nawrocki D.K., Isopi L.A., Williams D.M., Casimiro D.R., Chin S., et al. Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 93 10 (2004) 2458-2475
38. Croyle M.A., Cheng X., and Wilson J.M. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Therapy 8 17 (2001) 1281-1290
39. Thorner A.R., Lemckert A.A.C., Goudsmit J., Lynch D.M., Ewald B.A., Denholtz M., et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 80 24 (2006) 12009-12016
40. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 7090 (2006) 239-243
41. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 16 (2003) 8729-8735
42. Brett S.J., Blau J., Hughes-Jenkins C.M., Rhodes J., Liew F.Y., and Tite J.P. Human T cell recognition of influenza A nucleoprotein-specificity and genetic restriction of immunodominant T helper cell epitopes. J Immunol 147 3 (1991) 984-991
43. Finkelstein D.B., Mukatira S., Mehta P.K., Obenauer J.C., Su X., Webster R.G., et al. Persistent host markers in pandemic and H5N1 influenza viruses. J Virol 81 19 (2007) 10292-10299